Date: 2014-03-31
Type of information: R&D agreement
Compound:
Company: Lundbeck (Denmark) Astellas (Japan) Pfizer (USA - NY) Roche (Switzerland) Eli Lilly (USA - IN) Lieber Institute for Brain Development (USA - MD)
Therapeutic area: CNS diseases
Type agreement: R&D
Action mechanism:
Disease:
Details: * On March 31, 2014, Lundbeck, together with a number of other companies, is now entering into a collaboration with the Lieber Institute, which has the world’s largest collection of human brains from patients with psychiatric disorders. This collaboration will enable Lundbeck’s researchers to take decisive steps towards new and better treatment of the debilitating and life-long brain disease that is schizophrenia.
This joint project provides a unique opportunity to investigate how genes affect brain development and disorders of the brain. Based on knowledge of the biology of brain disease, researchers will simply be able to look at the brains of both sick and healthy individuals and establish a nuanced picture of how the biology of the disease can be expressed. Researchers involved in this project will identify the biological and genetic processes that control development of the healthy brain and how these processes go wrong in brain disorders. In addition to Lundbeck the project also involves the pharmaceutical companies Astellas, Pfizer, Roche and Eli Lilly. Researchers from these otherwise competing companies will openly cooperate with researchers from the Lieber Institute on advancing brain-science and only there after start competing on developing new medicines.
Financial terms:
Latest news:
